Most Read Articles
31 Jul 2018
New drug applications approved by US FDA as of 16 - 31 July 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

Tristan Manalac, 16 Dec 2017
Methylphenidates, but not amphetamines, when taken during the first trimester of pregnancy, slightly increase the risk of cardiac congenital malformations, a recent study has shown.
Pearl Toh, 4 days ago
Low-density lipoprotein cholesterol (LDL-C) levels remained high in many patients with stable or acute coronary heart disease (CHD) in Asia, despite having a very high risk of recurrent cardiovascular (CV) events, indicating that the use of lipid-lowering therapies and lipid monitoring were inadequate.

Hydrochlorothiazide ups risk of nonmelanoma skin cancer

09 Dec 2017

Hydrochlorothiazide (HCTZ) appears to significantly increase the risks of nonmelanoma skin cancer (NMSC), particularly squamous cell carcinoma (SCC), a recent study has shown.

Researchers compared the patterns of HCTZ use between 80,162 NMSC patients and 1,603,345 age- and sex-matched controls. Those with SCC of the lip were excluded.

Conditional logistic regression analysis was used to calculate for the risk of basal cell carcinoma (BCC) or SCC with the frequency of HTCZ use. Adjustments were performed for potential confounder such as other medications and comorbidities.

The rate of high HCTZ usage in BCC patients was higher than in matched controls (2.7 vs 2.1 percent; odds ratio [OR], 1.29; 95 percent CI, 1.23 to 1.35). Similarly, significantly more SCC patients were high HCTZ users than matched controls (10.0 vs 2.8 percent; OR, 3.98; 3.68 to 4.31).

HCTZ use also showed a dose-response relationship with BCC and SCC, with those at the highest categories of exposure having the highest risks (OR for BCC, 1.54; 1.38 to 1.71; p<0.001 for trend; OR for SCC, 7.38; 6.32 to 8.60; p<0.001 for trend).

Similar trends were observed when the participants were grouped according to sex, age and tumour localization. Notably, none of the other diuretics and hypertensives showed significant relationships with the risk of SCC and BCC.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
31 Jul 2018
New drug applications approved by US FDA as of 16 - 31 July 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

Tristan Manalac, 16 Dec 2017
Methylphenidates, but not amphetamines, when taken during the first trimester of pregnancy, slightly increase the risk of cardiac congenital malformations, a recent study has shown.
Pearl Toh, 4 days ago
Low-density lipoprotein cholesterol (LDL-C) levels remained high in many patients with stable or acute coronary heart disease (CHD) in Asia, despite having a very high risk of recurrent cardiovascular (CV) events, indicating that the use of lipid-lowering therapies and lipid monitoring were inadequate.